The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from price gouging.

Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" prescription price hikes of 1,000% or more.

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, OptumRx and Express Scripts.

Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs,

The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension drug.

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, cardiovascular diseases, and HIV, specifically, the big three players in the sector – CVS' Caremark,

A new Federal Trade Commission (FTC) report found that the three largest Pharmacy Benefit Managers (PBMs) have taken in large profits on lifesaving medicine for heart disease, cancer and HIV. Pharmacy Benefit Managers are third-party companies connected to pharmacies that are intermediaries between insurance providers and pharmaceutical manufacturers and claim to reduce consumer costs.

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,

Agency commissioners voted unanimously on Tuesday to publish the report, which makes a similar attack on the drug middlemen as the agency’s first report, but draws on more data.